ZA201207790B - Methods and compositions for inhibiting hiv transmission - Google Patents

Methods and compositions for inhibiting hiv transmission

Info

Publication number
ZA201207790B
ZA201207790B ZA2012/07790A ZA201207790A ZA201207790B ZA 201207790 B ZA201207790 B ZA 201207790B ZA 2012/07790 A ZA2012/07790 A ZA 2012/07790A ZA 201207790 A ZA201207790 A ZA 201207790A ZA 201207790 B ZA201207790 B ZA 201207790B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
inhibiting hiv
hiv transmission
transmission
Prior art date
Application number
ZA2012/07790A
Other languages
English (en)
Inventor
Grant Thomas Rawlin
Damian Francis John Purcell
Robert John Center
Marit Kramski
Roy Michael Robins-Browne
Gottfried Lichti
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Publication of ZA201207790B publication Critical patent/ZA201207790B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2012/07790A 2010-04-09 2012-10-17 Methods and compositions for inhibiting hiv transmission ZA201207790B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (1)

Publication Number Publication Date
ZA201207790B true ZA201207790B (en) 2013-06-26

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/07790A ZA201207790B (en) 2010-04-09 2012-10-17 Methods and compositions for inhibiting hiv transmission

Country Status (12)

Country Link
US (1) US20130022619A1 (OSRAM)
EP (1) EP2555798B1 (OSRAM)
JP (1) JP6026402B2 (OSRAM)
CN (1) CN103167881B (OSRAM)
AP (1) AP3469A (OSRAM)
AU (2) AU2011238431B2 (OSRAM)
BR (1) BR112012025678A2 (OSRAM)
CA (1) CA2795853A1 (OSRAM)
MX (1) MX343505B (OSRAM)
RU (1) RU2594249C2 (OSRAM)
WO (1) WO2011123900A1 (OSRAM)
ZA (1) ZA201207790B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077130B2 (en) 2013-09-27 2021-08-03 Duke University Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
CA2999917A1 (en) * 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
WO2017062069A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless spring torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
CN116171165A (zh) * 2020-06-10 2023-05-26 墨尔本大学 Hiv-1抗体
AU2022272307A1 (en) 2021-05-12 2023-11-16 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
WO2024108050A1 (en) 2022-11-16 2024-05-23 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
CN101912610A (zh) * 1999-06-24 2010-12-15 约翰·霍普金斯大学 用于预防hiv经上皮传播的组合物和方法
EP1322292B1 (en) * 2000-09-28 2007-01-03 Novartis Vaccines and Diagnostics, Inc. Microparticle compositions and methods for the manufacture thereof
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
WO2010096042A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Also Published As

Publication number Publication date
JP6026402B2 (ja) 2016-11-16
CN103167881A (zh) 2013-06-19
BR112012025678A2 (pt) 2017-07-18
AU2011238431A1 (en) 2012-11-08
RU2594249C2 (ru) 2016-08-10
EP2555798B1 (en) 2016-06-22
AU2011238431B2 (en) 2016-10-06
CA2795853A1 (en) 2011-10-13
MX343505B (es) 2016-11-04
JP2013523783A (ja) 2013-06-17
MX2012011574A (es) 2013-03-05
AU2017265055A1 (en) 2019-06-06
EP2555798A1 (en) 2013-02-13
AP3469A (en) 2015-11-30
CN103167881B (zh) 2017-06-16
WO2011123900A1 (en) 2011-10-13
US20130022619A1 (en) 2013-01-24
RU2012142999A (ru) 2014-05-20
AP2012006519A0 (en) 2012-10-31
EP2555798A4 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
IL224390B (en) Compositions and methods for targeted thermal modulation
HRP20171343T1 (hr) Mješavine
ZA201209201B (en) Cyclopropene compositions
GB201009549D0 (en) Compositions
ZA201209259B (en) Uses and compositions
PH12013500698A1 (en) Hair-mending compositions and associated methods
AP3469A (en) Methods and compositions for inhibiting hiv transmission
PL2579875T3 (pl) Kompozycje zawierające buprenorfinę
GB201010954D0 (en) Compositions
EP2625231A4 (en) INK PRESERVATIVE COMPOSITIONS
GB201002861D0 (en) Compositions
GB201018650D0 (en) Methods and compositions
EP2541102A4 (en) TRANSMISSION
IL225952A0 (en) preparations@rokkhot
HUE040161T2 (hu) Készítmények és módszerek a burgonya kórokozóinak gátlására
GB201014591D0 (en) Compositions
LT2614000T (lt) Transmisija
GB201007790D0 (en) Compositions
GB201001265D0 (en) Transmission
GB201019606D0 (en) Compositions
GB201008043D0 (en) Compositions
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods
GB201009767D0 (en) Compositions and methods
GB201019291D0 (en) Compositions and uses